Until prospective data are available, researchers recommend that patients with ER-low breast cancer “should be counseled regarding the potential benefit” of adjuvant endocrine therapy.

Taking time to get a second opinion on breast cancer treatment did not significantly alter the time to treatment, which still ...

When the researchers looked at LLM performance for individual treatments and tests, they found that AI generally demonstrated “high accuracy for adjuvant endocrine therapy and targeted therapy ...

A prognostic index can be used to identify patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer who can safely forgo adjuvant chemotherapy as well as patients who require ...

Standard of care for early ER-positive breast cancer includes 5-10 years of adjuvant endocrine therapy, which has been shown to reduce recurrence, decrease breast cancer mortality, and improve OS ...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 5, 2025, the Compensation ...

It is hoped that chemotherapy could be used with hormone therapy and in the adjuvant setting, as is the case in many other solid tumors, in patients with 'high-risk' prostate cancer who are ...